Internal Medicine, Endocrinology, Diabetes, & Metabolism · San Carlos, CA
NPI
1558535203
Since 2008
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1660 San Carlos Ave
San Carlos, CA, 94070
Phone (650) 591-9933
Groups this clinician bills Medicare through
Medicare paid, 2024
$343K
3,245 services
Medicare patients, 2024
364
Average age 74
Drug cost, 2024
$5.8M
5,925 prescriptions
Company payments, 2025
$78K
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Leila Chaychi was code 99215 (office e&m - established), 1,649 times for 351 patients. In total Leila Chaychi billed 3,245 services in 17 codes, and Medicare paid $343K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-07-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 1,649 | 351 | $150.40 | $248K |
| 99458 E&M - Miscellaneous | Office | 473 | 116 | $34.26 | $16K |
| 99457 E&M - Miscellaneous | Office | 471 | 115 | $43.89 | $21K |
| 95250 Test - Miscellaneous | Office | 124 | 88 | $153.40 | $19K |
| 76536 Ultrasound - Nonspecific | Office | 101 | 94 | $113.54 | $11K |
| 99453 E&M - Miscellaneous | Office | 58 | 36 | $21.31 | $1,236 |
| 99454 E&M - Miscellaneous | Office | 58 | 36 | $51.36 | $2,979 |
| 99205 Office E&M - New | Office | 50 | 50 | $181.70 | $9,085 |
| 10005 Other Organ Systems | Office | 33 | 32 | $129.90 | $4,287 |
| 99212 Office E&M - Established | Office | 29 | 26 | $49.16 | $1,426 |
| 10006 Other Organ Systems | Office | 27 | 27 | $54.35 | $1,467 |
| 99214 Office E&M - Established | Office | 24 | 22 | $113.11 | $2,715 |
By year: 2022 $498K for 15,388 services; 2023 $399K for 6,525 services; 2024 $343K for 3,245 services.
Medicare prescription drug claims, 2024
In 2024, the drug Leila Chaychi prescribed most often to Medicare patients was Mounjaro (Tirzepatide), with 957 prescriptions and refills. In total Leila Chaychi wrote 5,925 Medicare prescriptions that cost $5.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | 957 | 1,280 | 167 | $1.3M |
| Synthroid Levothyroxine Sodium | 372 | 826 | 85 | $37K |
| Ozempic Semaglutide | 304 | 486 | 87 | $448K |
| Synjardy Xr Empagliflozin/Metformin Hcl | 261 | 515 | 57 | $318K |
| Levothyroxine Sodium Generic | 207 | 441 | 73 | $3,048 |
| Rosuvastatin Calcium Generic | 181 | 462 | 58 | $4,643 |
| Losartan Potassium Generic | 170 | 430 | 49 | $1,732 |
| Jardiance Empagliflozin | 170 | 335 | 41 | $191K |
| Atorvastatin Calcium Generic | 146 | 330 | 41 | $3,081 |
| Metformin Hcl Generic | 146 | 372 | 44 | $2,730 |
| Tresiba Flextouch U-200 Insulin Degludec | 134 | 304 | 42 | $177K |
| Metformin Hcl Er Metformin Hcl | 123 | 283 | 40 | $1,396 |
| Synjardy Empagliflozin/Metformin Hcl | 111 | 224 | 31 | $120K |
| Levoxyl Levothyroxine Sodium | 108 | 224 | 28 | $4,154 |
| Calcitriol Generic | 85 | 201 | 21 | $1,667 |
Brand drugs: 3,398 claims; generic drugs: 2,370 claims; opioid claims: 12.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Leila Chaychi $78K ($78K in general payments such as food, travel and fees) from 26 companies. The largest payer was Lilly USA, LLC with $48K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 64 | $48K |
| Alexion Pharmaceuticals, Inc. AZN | 22 | $25K |
| Neurocrine BioSciences, Inc. NBIX | 6 | $3,381 |
| Amgen Inc. AMGN | 18 | $393 |
| Madrigal Pharmaceuticals MDGL | 7 | $156 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 9 | $135 |
| Radius Health, Inc. | 3 | $95.58 |
| Recordati_rare_diseases_inc. | 4 | $82.8 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $71.11 |
| Dexcom, Inc. DXCM | 2 | $66.64 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.